

Gordon Hamilton

*Chief Executive Officer, Co-Founder of Depixus*

Gordon Hamilton co-founded Depixus and has led the company since its inception. He has played an important role in defining the company's vision and strategy, has helped to raise over €50m to finance its activities to-date, and has contributed to the company's core inventions both in instrumentation and biology. Prior to Depixus, he was Medical Director at ChemoCentryx, a Californian drug-discovery company (subsequently acquired by Amgen), where he helped the company to advance its novel chemokine-targeting drugs through Phases I and II of clinical development. Before ChemoCentryx, he worked as a medical doctor in emergency medicine in the UK and founded and built The Electives Network, an international medical education company. He has a first-class master's degree in Physiological Sciences from the University of Oxford, degrees in Medicine and Surgery from Imperial College School of Medicine, and an MBA from INSEAD.

